insurance and government-based insurance. 4 Data found in the Commercial Claims and Encounters (CCAE) database contains de-identified individual-specific details for those covered by 1 of over 300 contributing employers that sponsor private health insurance, as well as data on both the spouses and the dependents of the employees. 2 Data included within this database are obtained from inpatient and outpatient medical claims, outpatient prescription claims, clinical utilization records, and healthcare expenditures. This comprehensive collection of data allows for analysis of diagnoses (using International Classification of Disease, 9th edition, Clinical Modifications [ICD-9-CM] codes) and procedures (using Current Procedural Terminology [CPT] codes) for which claims are submitted, as well as the resultant costs, reimbursements, and out-of-pocket expenses borne by patients, provider systems, and payers. 3, 5, 6 Certain patient demographic and hospital characteristics, however, such as race, income, and hospital or physician volume, are not included in the database. Nonetheless, for studies that focus on health states of working-age individuals or their dependents, this database provides high-quality claims data to identify healthcare utilization patterns among this cohort of patients. Although not representative of all beneficiaries in the Medicare and Medicaid populations, these two MarketScan databases provide the ability to obtain granular healthcare utilization data regarding two at-risk populations that may be of particular interest to health services researchers.
MarketScan Supplemental Databases
The 11 supplemental databases within the MarketScan family are listed in ►Table 1. These databases are designed to augment the information garnered from the core databases described earlier by providing more clinically oriented data, in areas that may be of specific interest to economists, health services researchers, and market analysts. Several of these supplementary databases may be of interest to clinical health services researchers, particularly in the fields of gastroenterology and colorectal surgery. The MarketScan Health Risk Assessment database contains patient selfreported data on behaviors (e.g., smoking, dietary habits) that are otherwise absent in the core databases, and may be of particular use to researchers interested in preoperative risk stratification of patients undergoing elective procedures. 8 The MarketScan Benefit Plan Design database offers important advantages that are typically inaccessible to large national databases, containing data on home healthcare utilization, physical therapy services, and extended care or skilled nursing facility information. 
Strengths
The primary benefit of MarketScan is that it offers a detailed overview of "real-world" healthcare utilization and outcomes for large subset of the U.S. population. While continuous enrollment in an insurance plan is necessary to link patient information across encounters, loss of data due to a change in health plans is attenuated by using employerprovided data to track patients across plans, since people change insurance plans more frequently than they change employers. Additional advantages of this particular family of databases, which are also outlined in ►Fig. 2, include the full integration of inpatient and outpatient care, emergency care services, along with outpatient pharmaceutical data, on a per-enrollee level. 3 With this extensive tracking scheme, MarketScan follows patient encounters from a prehospitalization setting, through any inpatient care that was administered, and then through any posthospitalization clinic visits or outpatient pharmaceutical claims. 6, 10 In studying patients with colorectal diseases, for whom care pathways often traverse the full spectrum of healthcare settings, accessing complete data for all of the settings is essential for building a complete picture of a particular disease process. Additionally, rather than relying upon prescription practices as a proxy for medication usage, MarketScan identifies prescriptions that were actually filled by the patients, and provides a breakdown of reimbursement and out-of-pocket expenses.
5
Using the Health Plan Benefit Design supplemental database, researchers can also track claims for visiting nurses, rehabilitation facilities, and other aspects of care that are essential for evaluating the full economic impact of diseases. Furthermore, the data present in these databases are based only on claims that have been fully paid or adjudicated, thereby increasing the accuracy of claims data. Finally, despite the extensive linkage and continuity of patient-level data present within the databases, these databases maintain HIPAA (Health Insurance Portability and Accountability Act) compliance through rigorous measures to ensure protection of patient privacy, and all data are de-identified to users who obtain access to the database.
Limitations
Despite many strengths, the MarketScan databases do have several limitations that are important to consider when designing potential studies. Perhaps their most considerable limitation is the fact that the CCAE database represents working-age patients covered by private insurance that is supplied by employers who contribute to the database, rather than a random sample from the U.S. population, and therefore are not representative of the U.S. population. With the exception of the MMS database, individuals or their family members within the CCAE and the MDCR mandatorily possess some form of employer-based health insurance, which makes the dataset not nationally representative. Moreover, the employers that contribute to MarketScan data represent large employers, with weaker representation from small or medium size firms. As a result of these weaknesses, these data cannot be weighted to reflect a national sample, nor are results obtained from this database always generalizable to the U.S. population as a whole.
Other limitations derive from the fact that, similar to other claims-based databases, the validity of any claims-based database is reliant upon the accuracy of the medical coding and billing data that it contains. Additionally, the scope of encounters captured by MarketScan is limited to only those for which a claim was submitted; thus, certain comorbidities, medications, or procedures may not be identified. For example, data on over-the-counter medication purchases is not contained in the MarketScan database. Furthermore, while data on prescriptions fills are available, this does not necessarily translate into patient adherence with the prescribed dosing schedules. A study by Lauffenburger et al identified an approximately 10% discrepancy in capturing warfarin utilization by using claims data from this database, potentially due to some patients having prescriptions filled outside of the context of their standard prescription benefit.
11 Lastly, within the core databases, many important demographic and outcomes detailssuch as race, smoking status, and mortality-are not available without the purchase of supplemental databases, thereby limiting the scope of studies that can be performed with the core datasets.
Obtaining Access to the MarketScan Databases
Currently, there are several ways in which researchers can access the MarketScan databases for clinical research projects. The decision for which option to pursue depends primarily on the funding sources and the specific clinical questions posed by the researcher. Currently, academic institutions may qualify for an academic license from Truven Health Analytics, which typically includes access to both the CCAE and the MDCR databases (containing data on 40-50 million patients per available year). This yearly license may then be utilized by multiple faculty members at a single institution. For researchers who would prefer to conduct a single specific study, external funding can be used to obtain a single study license through Truven Health Analytics to answer a particular research question. Data that are available within the 11 supplemental databases (e.g., Health Risk Assessment Database, Laboratory Database, etc.) include additional clinical information on various subsets of patients within the core databases. However, for researchers who want to limit their analysis to a particular subset of patients with complete data (i.e., only patients who have data present in the Laboratory Database), Truven offers smaller licenses that give researchers access to the specialized dataset of interest, as well as the patients' corresponding medical and pharmaceutical claims data that are present within the core databases, without having to obtain access to the entire population within the core databases.
After a license is obtained, the data are provided in SASformatted data files, which researchers can then access and use to analyze the licensed data. Further information can be obtained from https://marketscan.truvenhealth.com/marketscanportal/, and specific inquiries regarding the use of Truven MarketScan databases may be directed via email to marketscan@truvenhealth.com.
Colorectal and Gastrointestinal Clinical Research Using MarketScan
Within the fields of colorectal surgery and gastroenterology, the MarketScan databases have been utilized to address a variety of epidemiologic and health services research questions. Below are several illustrative examples of these studies, from a variety of institutions, which utilize these data to answer a wide scope of research queries.
Epidemiology
Given the detailed pharmaceutical data available in MarketScan databases, epidemiologic studies focusing on medication exposures and potential outcomes can be assessed. A good example of this was a case-control study performed by Sehdev et al at the University of Chicago: from 2005 to 2010, individuals with a prior diagnosis of diabetes mellitus (DM) and a new claim for colorectal cancer (CRC) within a 12-month period were identified within the MarketScan CCAE database. 12 These were matched 2:1 with controls, who had a diagnosis of DM but no diagnosis of CRC, by age, sex, and geographical region. The exposure of interest in this study was metformin use within 12 months prior to the diagnosis of CRC (suggesting long-term or chronic use), and the authors hypothesized that prior metformin use would be associated with a reduction in CRC development. Using conditional logistic regression and controlling for available comorbidities and concurrent medication use, the authors identified a significant reduction in the odds (odds ratio [OR]: 0.85, 95% confidence interval [CI]: 0.76-0.95, p < 0.007) of developing CRC among those with prior metformin use. However, when the authors subsequently controlled for healthcare utilization (including outpatient visits and number of hospitalizations), the reduction in odds of developing CRC was no longer significantly. Given that CRS is relatively slow growing neoplasm over the course of years, and the exposure to metformin was assessed for only 1 year, the lack of association may be secondary to study design, or there may be a true lack of association. The authors' ability to control for healthcare utilization in this study represents one of the unique adjuncts in this database that can be taken advantage of within epidemiologic research.
Time Trends
When researching a particular type of diagnostic or therapeutic encounter within the healthcare field, the MarketScan databases allow for the identification of trends in utilization over time. Peery and colleagues used the three main MarketScan databases (Commercial, Medicare, and Medicaid) to identify the incidence and costs of three types of gastrointestinal endoscopic procedures in 2009: upper endoscopy (including esophagogastroduodenoscopy, endoscopic ultrasonography, and enteroscopy), lower endoscopy (including colonoscopy, flexible sigmoidoscopy, endorectal ultrasound, and pouchoscopy), and endoscopic retrograde cholangiopancreatography (ERCP). 13 The incidence of these procedures was standardized to the age and gender distribution of the entire U.S. population, and found to be 6.9 million for upper endoscopies, 11.5 million for lower endoscopies, and 228,000 for biliary endoscopies. Estimates for total outpatient costs were $12.3 billion, $19.2 billion, and $900 million, respectively. Then, using the MarketScan CCAE database, trends in time over a 10-year period (2000-2009) for each of the three types of endoscopic procedures were identified (shown in ►Fig. 3). Among commercially insured patients, the authors identified a significant increase for both upper and lower endoscopy over that period of time (54 and 17%, respectively), but an overall decrease (by 16%) in the use of ERCP.
Rare Diseases/Occurrences
With the large numbers of patients present within the databases, the MarketScan databases are able to capture relatively large numbers of diagnoses and outcomes that are otherwise infrequent or rare. 
Health Economic Modeling
The MarketScan database was used by Malone et al from the University of Arizona in developing a Markov model for determining the health care costs associated with varying degrees of Crohn's disease severity. 17 The Markov modeling is a method that can be utilized to determine costeffectiveness or comparative effectiveness of two different hypothetical populations, based on imputation of a copious amount of best-available real-world data. Data from both the MarketScan CCAE database and the MarketScan Medicare Supplemental and Coordination of Benefits database were used as data sources for this study. Because of the detailed data obtained through procedural claims, diagnostic codes (to identify both symptoms and complications), and medication usage, the authors were able to use the American College of Gastroenterology definitions to identify the disease states of remission, mild-moderate, moderate-severe, and severe fulminant. Healthcare costs per 6-month interval were identified within the database and used to estimate the monthly costs associated with each level of disease severity. More importantly, since the data within MarketScan are longitudinal, the authors were able to determine probabilities associated with transitioning from one severity state to another (e.g., progressing from a less severe state to a more severe state, or vice versa, or remaining in the same severity state), based on the observed patterns of disease severity identified within the study population over time. These probabilities were used to parameterize the model, as were the associated costs estimated from the study. Finally, by using values from the literature regarding qualityadjusted life years (QALYs)-the most common metric used in comparative effectiveness research-the authors demonstrated that the costs of care required to gain QALYs were significantly higher among more severe levels of disease: for example, among male patients, costs per QALY were $2,896 for disease in remission, $8,428 for mild-moderate disease, $11,518 for moderate-severe disease, and $69,277 for severe-fulminant disease. Truven Health Analytics MarketScan Databases Kulaylat et al. 59
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